What type of study is this?

September 28, 2025Therapeutic Advances in Medical OncologyOpen Access

Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane–carboplatin-based neoadjuvant chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

QHQiuyan HuangSouth China Agricultural University KHKai HuangFujian Medical University JQJin-Xian QianSuzhou Municipal Hospital

Discussion

Member takes

Implication

Retrospective cohort study evaluates platelet-to-lymphocyte ratio as a prognostic biomarker for overall survival in patients with HER2-negative breast cancer, highlighting its significance.

Key Points

High platelet-to-lymphocyte ratio predicts poorer overall survival in patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy.
Among 178 patients, high platelet-to-lymphocyte ratio was found in 52.8%, with significant links to overall survival (p = 0.001) in non-pCR cases.
Retrospective cohort study analyzed data from two hospitals, employing multivariate Cox regression to assess prognostic value for overall survival.
The nomogram incorporating platelet-to-lymphocyte ratio, estrogen receptor status, and clinical stage demonstrates strong predictive performance.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68d90bc941e1c178a14f717b https://doi.org/10.1177/17588359251369041

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study evaluates platelet-to-lymphocyte ratio as a prognostic biomarker for overall survival in patients with HER2-negative breast cancer, highlighting its significance.

Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane–carboplatin-based neoadjuvant chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane–carboplatin-based neoadjuvant chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider